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ABSTRACT
Patients with Staphylococcus aureus bacteraemia (SAB) who received either inappropriate or appropriate
empirical therapy were compared by using two risk stratiﬁcation models: (1) a cohort study using a
propensity score to adjust for confounding by empirical treatment assignment; and (2) a propensity-
matched case-control study. Inappropriate empirical therapy was modelled on the basis of patient
characteristics, and included in the multivariate model to adjust for confounding. For case-matching
analysis, patients with inappropriate empirical therapy (cases) were matched to those with appropriate
empirical therapy (controls) on the basis of the propensity score (within 0.03 on a scale of 0–1). In total,
238 patients with SAB were enrolled in the cohort study. Characteristics associated with inappropriate
empirical therapy were methicillin resistance, underlying haematological malignancy, no history of
colonisation with methicillin-resistant S. aureus, and a long hospital stay before SAB. These variables
were included in the propensity score, which had an area under the receiver operating characteristics
curve of 85%. In the cohort study, SAB-related mortality was 39% (45 ⁄ 117) for inappropriate empirical
therapy vs. 28% (34 ⁄ 121) for appropriate empirical therapy (odds ratio (OR) 1.60; 95% CI 0.93–2.76).
After adjustment for independent predictors for mortality and the propensity score, inappropriate
empirical therapy was not associated with mortality (adjusted OR 1.39; 95% CI 0.62–3.15). In the
matched case-control study (50 pairs), SAB-related mortality was 32% (16 ⁄ 50) for inappropriate
empirical therapy and 28% (14 ⁄ 50) for appropriate empirical therapy (McNemar’s test; p 0.85; OR 1.15;
95% CI 0.51–2.64). In conclusion, inappropriate empirical therapy resulted in only a slight tendency
towards increased mortality in patients with SAB.
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INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA)
has become a worldwide problem [1], and the use
of vancomycin has escalated rapidly as the pre-
valence of MRSA infections has increased. How-
ever, vancomycin use is associated with an
increased prevalence of vancomycin-resistant
enterococci [2], while the recent emergence of S.
aureus with enhanced resistance to vancomycin is
associated with prolonged treatment with vanco-
mycin or glycopeptides [3,4]. The possible impact
on mortality of inappropriate empirical therapy
for S. aureus bacteraemia (SAB) is important,
given the increase in MRSA and the concern that
increased use of vancomycin might lead to further
resistance in Gram-positive bacteria. Several
observational studies have reported conﬂicting
results regarding the impact of delayed treatment
on the outcome of patients with SAB [5–11].
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However, previous studies did not adjust ade-
quately for the bias related to the appropriateness
of empirical antibiotic therapy, and it remains
unclear whether an initial delay in appropriate
treatment of SAB affects the outcome adversely.
Randomised clinical trials to determine the
impact of initial delay in appropriate antibiotic
treatment on the outcome of SAB are neither
feasible nor ethical. Propensity scoring is a
powerful tool for reconstructing a situation sim-
ilar to random assignment, albeit only with
respect to observed prognostic variables [12,13];
i.e., an adjustment using propensity scores
attempts to compensate for the bias created by
unequal chances of receiving the empirical anti-
biotic treatment. In addition, propensity scoring is
a useful method for matching covariables retro-
spectively in a non-randomised study that has the
potential to reduce selection bias [14,15]. The
purpose of the present study was to compare the
outcome in patients with SAB who received
inappropriate empirical therapy with those who
received appropriate empirical therapy by using a
risk stratiﬁcation model to adjust for potential
differences between the two groups.
PATIENTS AND METHODS
Study population and microbiological tests
Seoul National University Hospital is a university-afﬁliated
tertiary hospital with 1500 beds. The hospital provides spe-
cialised medical and surgical care, including bone marrow
transplantation for adult (aged > 15 years) patients. All
patients with blood cultures positive for S. aureus were
identiﬁed from a retrospective review of the computerised
records of the Clinical Microbiology Laboratory between
1 January 1998 and 31 October 2001. Only the ﬁrst clinically
signiﬁcant episode of SAB for each patient was included in the
analysis. Patients who had SAB as part of a polymicrobial
bloodstream infection were excluded.
Identiﬁcation of S. aureus was done with VITEK GPI Cards
(bioMe´rieux, Hazelwood, MO, USA). Antibiotic susceptibilit-
ies were determined using the NCCLS disk-diffusion method
[16].
Study design
The ﬁrst part of the study was a retrospective cohort study
including total SAB. The outcome of patients receiving inap-
propriate empirical antibiotic treatmentwas comparedwith that
of patients receiving appropriate empirical antibiotic treatment.
The second part of the study was a matched (1:1) case-control
study. For the purpose of this study, patients with SAB who
were treatedwith an inappropriate empirical antibiotic regimen
were deﬁned as ‘cases’, while those treated with an appropriate
empirical antibiotic regimen were deﬁned as ‘controls’.
Deﬁnitions
SAB was classiﬁed as ‘community-acquired’ if S. aureus was
isolated from blood cultures taken within 72 h of admission,
provided the patient was not transferred from another
hospital, but had suggestive symptoms or signs of infection
upon admission [17]. Otherwise, SAB was classiﬁed as
hospital-acquired. A history of MRSA colonisation was
deﬁned as a case in which MRSA had been isolated from
any specimens (i.e., sputum, wound or urine) within the
6 months preceding SAB. Neutropenia was deﬁned as
absolute neutrophil counts of 500 ⁄mm3 when bacteraemia
occurred.
Severity of underlying illness was classiﬁed according to
McCabe and Jackson’s criteria: rapidly fatal when death was
expected within a period of days or weeks; ultimately fatal
when death was expected within a period of months or years;
and non-fatal when death was not expected [18,19]. In
addition, severity of underlying illness was evaluated using
the Charlson weighted index of co-morbidity, which has been
demonstrated to be a useful scoring system to control
co-morbidity in patients with SAB [20].
Antibiotic treatment and outcome
Decisions regarding empirical antibiotic regimens were the
responsibility of the primary-care physicians. The empirical
antibiotic treatment was considered appropriate if the therapy
given intravenously within 48 h of the onset of bacteraemia
included at least one antibiotic to which the isolate was
susceptible [8,9,17].
The treatment outcomes were assessed 12 weeks after the
onset of SAB according to the following criteria: cure
(resolution of clinical signs of infection during therapy and
no evidence of recurrent SAB within 12 weeks); recurrence
(clinical resolution of signs and symptoms of infection during
therapy, but recurrent SAB within 12 weeks); non-SAB-
related mortality (death caused by underlying diseases or
another process, with no evidence of S. aureus infection at the
time of death); and SAB-related mortality (death occurred
before the resolution of symptoms or signs, or within 7 days
of the onset of SAB, in the absence of any other explanation)
[7,21].
Propensity score
Logistic regression was used to model the probability of
treatment with inappropriate empirical therapy, based on
observed baseline characteristics (Table 1). A forward step-
wise approach was used, with p £ 0.20 as the limit for
selecting variables for entry into the model, and p £ 0.05 to
remain in the model. A variable that was considered to be a
clinically important risk-factor for inappropriate empirical
therapy, but that was not included in the model in this
procedure, was tested for confounding by adding it to the
model and examining its effects on the b coefﬁcient. Any
variable that caused substantial confounding (a change in the
b coefﬁcient of > 10%) was included in the ﬁnal model
[22,23]. Effect modiﬁcation between variables was examined
by using clinically important interaction terms [24]. The
adequacy of the propensity score in adjusting for the effect of
covariates of inappropriate treatment was assessed by testing
for differences within quintiles of propensity [12,25]. The
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overall discrimination of the model was expressed as the area
under the receiver operating characteristics (ROC) curve
[22,23,26].
Case-matching procedure
Patients who received inappropriate empirical therapy were
matched to patients who received appropriate empirical
therapy and had the closest propensity scores (within 0.03 on
a scale of 0–1) [27,28]. In the case of two or more potential
controls, selection was based on those subjects with the closest
ages [29]. This procedure was continued until all possible pairs
were identiﬁed. Control patients were chosen without know-
ledge of the patients’ survival status.
Statistical analysis
The results were analysed using SPSS v. 10.0 (SPSS, Inc.,
Chicago, IL, USA). Categorical variables were compared by
Fisher’s exact test or chi-square test, as appropriate, and
continuous variables were compared by the Mann–Whitney
U-test or Student’s t-test. All tests of signiﬁcance were two-
tailed; p values £ 0.05 were considered to be signiﬁcant. The
effect of inappropriate empirical therapy on SAB-related
mortality was analysed by performing multivariate analysis.
All the variables were candidates for these models with the
procedure described previously, while forcing the inappro-
priate empirical therapy and the propensity score into the
model [26,27]. McNemar’s test with continuity correction was
used to test the comparison of mortality between the matched
pairs.
RESULTS
Clinical characteristics
In total, 238 patients with clinically signiﬁcant
SAB were analysed. Of these, 127 (53%) had
MRSA bacteraemia, and 111 (47%) had methicil-
lin-susceptible S. aureus (MSSA) bacteraemia. The
median time to defervescence was 3.0 days (range
1–26 days). Thirty-nine (16%) patients had meta-
static infections. There were 186 (78%) hospital-
acquired cases and 52 (22%) community-acquired
cases; 117 (49%) patients were treated with an
inappropriate empirical antibiotic regimen, inclu-
ding 97 (76%) of 127 patients with MRSA bacter-
aemia, compared with 20 (18%) of 111 patients
with MSSA bacteraemia. At 12 weeks after the
onset of SAB, the overall death rate, SAB-related
death rate and rate of death caused by organisms
other than S. aureus were 43% (103 ⁄ 238), 33%
(79 ⁄ 238) and 10% (24 ⁄ 238), respectively. Among
79 patients whose death was related to SAB, this
occurred within 4 days of obtaining a blood
sample for culture in 30 (38%) patients, and
within 14 days in 68 (86%) patients. The median
time from the onset of bacteraemia to SAB-related
death was 9 days (range 1–32 days).
Among the 30 MRSA bacteraemia patients who
received an appropriate empirical antibiotic regi-
men, vancomycin (n = 28) or teicoplanin (n = 2)
was given within 2 days of the onset of SAB. Of
the 97 MRSA bacteraemia patients who received
inappropriate empirical antibiotic treatment, 77
(80%) were given a b-lactam ± an aminoglyco-
side (to which the isolates were resistant) within
2 days of the onset of SAB. A further eight (8%)
were given a quinolone ± an aminoglycoside, six
(6%) were given a b-lactam ± a quinolone, and
six (6%) received no parenteral antibiotics. Of the
91 MSSA bacteraemia patients who received an
appropriate empirical antibiotic regimen, 77 were
given a b-lactam (i.e., cefazolin or naﬁcillin) ± an
aminoglycoside, two were given a b-lactam +
clindamycin, and 12 were given vancomycin ± an
aminoglycoside within 2 days of the onset of SAB.
Of 20 MSSA bacteraemia patients receiving inap-
propriate empirical antibiotic treatment, 11 (55%)
were given piperacillin ± an aminoglycoside (to
which the isolates were resistant), four (20%)
Table 1. Baseline clinical characteristics of patients with
Staphylococcus aureus bacteraemia (SAB) who received
inappropriate or appropriate empirical antibiotic therapya
Clinical characteristics
Inappropriate
empirical
therapy (n = 117)
Appropriate
empirical
therapy (n = 121) p
Age (years, mean ± SD) 54.2 ± 16.4 55.5 ± 15.9 0.56
Male gender 75 (64.1) 81 (66.9) 0.65
Community-acquired infectionb 11 (9.4) 41 (33.9) < 0.001
Hospital stay before SAB
(days, median (range))b
22 (0–180) 7 (0–210) < 0.001
Methicillin resistanceb 97 (82.9) 30 (24.8) < 0.001
Primary sites of infection
Unknown primary siteb 52 (44.4) 41 (33.9) 0.10
Catheter-related infection 30 (25.6) 26 (21.5) 0.45
Pneumoniab 12 (10.3) 23 (19.0) 0.06
Soft tissue infectionb 4 (3.4) 15 (12.4) 0.01
Surgical wound infection 10 (8.5) 6 (5.0) 0.27
Infective endocarditis 2 (1.7) 3 (2.5) 0.68
McCabe classiﬁcation
Rapidly fatalb 48 (41.0) 35 (28.9) 0.05
Ultimately fatal 49 (41.9) 60 (49.6) 0.24
Non-fatal 20 (17.1) 26 (21.5) 0.39
Charlson weighted index
of co-morbidity (mean ± SD)
2.6 ± 1.5 2.4 ± 1.5 0.47
Underlying disease
Liver cirrhosis 19 (16.2) 25 (20.7) 0.38
Cancer 32 (27.4) 27 (22.3) 0.37
Haematological malignancyb 28 (23.9) 19 (15.7) 0.11
End-stage renal diseaseb 25 (21.4) 18 (14.9) 0.19
Infection acquired in ICUb 19 (16.2) 11 (9.1) 0.10
Previous antibiotic useb 88 (75.2) 55 (45.5) < 0.001
Previous surgeryb 35 (39.9) 18 (14.9) 0.005
History of MRSA colonisationb 19 (16.2) 16 (13.2) 0.51
Neutropeniab 23 (19.7) 14 (11.6) 0.09
SD, standard deviation; ICU, intensive care unit; MRSA, methicillin-resistant
S. aureus.
aData are presented as the number (%) of patients unless indicated otherwise.
bIncluded in the multivariate regression model of likelihood of being treated with
inappropriate empirical antibiotic treatment.
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were given a quinolone, and ﬁve (25%) received
no parenteral antibiotics. Antibiotic treatments
prescribed after susceptibility results were avail-
able did not differ between the inappropriate and
the appropriate empirical treatment groups.
Inappropriate empirical therapy and propensity
score
The characteristics of patients who received inap-
propriate or appropriate empirical therapy are
shown in Table 1. Patients who received inappro-
priate therapy were more likely to have a long
duration of hospital stay, to have MRSA infection,
to have rapidly fatal underlying diseases, and to
have a history of previous surgery or antibiotic
use. In contrast, patients who received appropri-
ate empirical therapy were more likely to have
community-acquired or soft-tissue infection.
Using these characteristics, a multivariate logistic
regression model was developed to calculate
the propensity score, a score that predicts the
patient’s probability of being treated with inap-
propriate empirical antibiotics (Table 2). The
score had an area under the ROC curve of 85%,
indicating good ability to discriminate patients
who received inappropriate empirical therapy
from those who received appropriate empirical
therapy.
Cohort study
In total, 238 patients were enrolled in the cohort
study. Baseline variables associated with
increased mortality in univariate analysis were
severity of underlying disease (rapidly or ulti-
mately fatal, and an increasing Charlson weighted
co-morbidity score), primary sites of infection
(unknown primary infection or pneumonia), and
underlying disease (liver cirrhosis or cancer). In
contrast, catheter-related infection was associated
with decreased mortality (Table 3).
Fig. 1 shows the durations of bacteraemia,
grouped according to the empirical treatment
regimen received. The mean times to deferves-
cence for inappropriate vs. appropriate empirical
antibiotic treatment were 6.5 ± 5.9 days vs.
4.5 ± 4.3 days, respectively (p 0.04). Patients
who received inappropriate empirical treatment
had more metastatic complications (21%; 24 ⁄ 117)
than those receiving appropriate empirical treat-
ment (12%; 15 ⁄ 121), although this difference was
not statistically signiﬁcant (p 0.12). Total deaths,
deaths caused by infections other than with
Table 2. Propensity score for a patient’s likelihood of
receiving inappropriate empirical antimicrobial therapy
Odds ratio (95% CI) p
Methicillin resistance 21.8 (10.2–46.7) < 0.001
Haematological malignancy 3.2 (1.4–7.5) 0.008
Long hospital stay before
bactaeremia (‡ 2 weeks)
2.2 (1.1–4.3) 0.03
Previous MRSA colonisation 0.3 (0.1–0.7) 0.007
MRSA, methicillin-resistant Staphylococcus aureus.
Table 3. Variables associated with mortality in 238 patients with Staphylococcus aureus bacteraemia (the cohort study)
Univariate analysis Multivariate analysisa
OR (95% CI) p Adjusted OR (95% CI) p
Old age (‡ 65 years) 1.78 (1.01–3.14) 0.22
Male gender 1.44 (0.80–2.57) 0.93
Community-acquired infection 0.97 (0.51–1.87) 0.93
Methicillin resistance 1.45 (0.84–2.51) 0.18
Severity of underlying disease
Rapidly or ultimately fatal 9.39 (2.81–31.35) < 0.001 5.71 (1.61–20.24) 0.007
Charlson weighted co-morbidity score 1.65 (1.36–2.00) < 0.001
Underlying diseases
Liver cirrhosis 3.03 (1.55–5.93) 0.001
Cancer 3.67 (1.99–6.78) < 0.001 2.48 (1.25–4.90) 0.009
End-stage renal disease 1.10 (0.55–2.20) 0.80
Haematological malignancy 0.93 (0.47–1.84) 0.84
Primary sites of infection
Unknown primary 3.69 (2.09–6.51) < 0.001 5.41 (2.68–10.92) < 0.001
Catheter-related infection 0.13 (0.05–0.34) < 0.001
Pneumonia 2.15 (1.04–4.44) 0.04 5.74 (2.31–14.23) < 0.001
Soft-tissue infection 0.48 (0.15–1.48) 0.19
Surgical wound infection 0.27 (0.06–1.21) 0.07
Inappropriate empirical treatment 1.60 (0.93–2.76) 0.09 1.39 (0.62–3.15) 0.42
OR, odds ratio; CI, conﬁdence interval.
aAdjusted for the propensity score of each patient’s likelihood of being treated with inappropriate empirical antibiotic therapy. As the Charlson weighted co-morbidity score
was highly correlated with McCabe and Jackson’s criteria, only one of these variables could be included in the ﬁnal model.
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S. aureus, recurrences and cures were 59 (50%), 14
(12%), two (2%) and 56 (48%), respectively,
among patients receiving inappropriate empirical
therapy vs. 44 (37%), ten (8%), four (3%) and 73
(60%), respectively, among patients receiving
appropriate therapy (p 0.03, p 0.34, p 0.68 and
p 0.05, respectively). SAB-related mortality was
39% (45 ⁄ 117) among patients receiving inappro-
priate empirical therapy vs. 28% (34 ⁄ 121) among
patients receiving appropriate therapy (p 0.09;
odds ratio (OR) 1.60; 95% CI 0.93–2.76).
In the multivariate analysis (adjusted for the
variables associated with SAB-related mortality
and the propensity score), inappropriate empir-
ical therapy was not associated with increased
mortality (adjusted OR 1.39; 95% CI 0.62–3.15;
Table 3).
The subgroup analysis including the rapidly
fatal cases showed that death occurred within
4 days of obtaining a blood sample for 30 (38%)
of 79 SAB-related deaths. Of these 30 patients, 15
(50%) received inappropriate empirical therapy,
while the remaining 15 received appropriate
empirical therapy (p 0.92). Fig. 2 shows the out-
come of S. aureus bacteraemia in association with
empirical antibiotic therapy and the severity of
underlying disease. Patients who received inap-
propriate empirical therapy and who had severe
underlying disease tended to have a worse out-
come than those who received appropriate empir-
ical therapy, although this difference was not
statistically signiﬁcant.
Matched case-control study
Fifty case patients who received inappropriate
empirical therapy were matched on the basis of a
propensity score similar to that of 50 patients who
received appropriate empirical therapy. It was not
possible to match adequately (within 0.03 on a
scale from 0.00 to 1.00) the propensity score for
empirical therapy for 67 other case patients who
received inappropriate empirical therapy. Base-
line clinical characteristics and outcomes in the
matched-cohort study are shown in Table 4. SAB-
related mortality was 32% (16 ⁄ 50) among patients
who received inappropriate empirical therapy vs.
28% (14 ⁄ 50) among patients who received appro-
priate empirical therapy (p 0.85; OR 1.15; 95% CI
0.51–2.64; McNemar’s test). Twenty-two matched
pairs had a concordant outcome (21 pairs sur-
vived and one died). Twenty-eight pairs had a
discordant outcome; in 15 pairs, the case patient
died and the control patient survived, while in 13
pairs, the case patient survived and the control
patient died (Table 5).
DISCUSSION
Empirical antibiotic regimens should be individ-
ualised according to the prevalent antibiotic
resistance pattern and the clinical setting of a
particular institution. However, MRSA infections
are not initially suspected for some patients, and
appropriate empirical treatment with anti-sta-
phylococcal antibiotics, especially vancomycin,
can be modiﬁed after 48 h, based on the availab-
ility of culture results and the clinical course of
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the patient. However, the effect of waiting for
preliminary microbiological results, especially for
patients with SAB, is unknown [30,31], although
several observational studies have reported con-
ﬂicting results [5–11]. However, most previous
studies have not been able to adjust comprehen-
sively for the variety of factors that inﬂuence the
receipt of inappropriate empirical therapy. The
present study investigated the association of
inappropriate empirical therapy with patient out-
come after adjusting for a wide range of poten-
tially confounding variables, using two different
analytical procedures. First, after adjustment for
independent predictors for mortality and treat-
ment selection bias using propensity score, mul-
tivariate analysis showed that inappropriate
empirical therapy was not associated with SAB-
related mortality (p 0.42; adjusted OR 1.39; 95%
CI 0.62–3.15). Second, the impact of an initial
delay in receiving appropriate antibiotics on
outcome in a matched cohort of 50 patients who
received inappropriate or appropriate empirical
therapy was also marginal (p 0.85; OR 1.15; 95%
CI 0.51–2.64).
One possible explanation for the above ﬁndings
is that most Gram-positive pathogens are not
usually rapidly lethal, unlike Gram-negative
organisms [32]. Several clinical trials with neutro-
penic cancer patients have shown that delay in
treatment with vancomycin does not affect the
outcome adversely [33–35], and it appears that
antibiotic treatment has little effect in reducing
mortality rates in patients with a rapidly fatal
outcome and SAB. This observation has also been
made for patients with pneumococcal bacterae-
mia who died during the ﬁrst 4 days of hospital-
isation [36], and in critically ill patients with early
mortality caused by sepsis [37]. It has also been
shown that an initial delay of 2 days in the use of
glycopeptide treatment has a marginal impact on
the outcome of MRSA bacteraemia [38]. These
ﬁndings are in agreement with the present study’s
ﬁnding that delayed treatment has a marginal
impact on the outcome of SAB.
These ﬁndings do not mean that empirical
antibiotic therapy is unimportant in SAB. If
S. aureus infection is suspected and the methicillin
resistance rate is high, vancomycin should be
prescribed until microbiological results are avail-
able. However, prudent use of vancomycin is
essential, and this may result in delayed treat-
ment of some patients with MRSA bacteraemia. A
short delay in the use of appropriate antibiotics
may not necessarily be associated with SAB-
related mortality, but may cause a more
prolonged period of bacteraemia (Fig. 1) and a
longer time to defervescence. However, empirical
Table 4. Clinical characteristics and outcomes of 50
matched pairs of patients with Staphylococcus aureus bac-
teraemia (SAB) (the matched case-control study)a
Clinical characteristics
Inappropriate
empirical
therapy (n = 50)
Appropriate
empirical
therapy (n = 50) p
Propensity score for inappropriate
empirical therapy (mean ± SD)
0.54 ± 0.25 0.54 ± 0.25 > 0.99
Age (years, mean ± SD) 48.7 ± 16.8 51.3 ± 16.9 0.44
Male gender 31 (62.0) 33 (66.0) 0.68
Community-acquired infection 5 (10.0) 2 (4.0) 0.44
Hospital stay before SAB
(days, median (range))
23 (0–180) 20 (0–110) 0.13
Methicillin resistance 30 (60.0) 30 (60.0) > 0.99
Primary sites of infection
Unknown primary site 19 (38.0) 16 (32.0) 0.53
Catheter-related infection 14 (28.0) 14 (28.0) > 0.99
Pneumonia 5 (10.0) 9 (18.0) 0.25
Soft-tissue infection 2 (4.0) 15 (8.0) 0.68
Surgical wound infection 4 (8.0) 6 (12.0) 0.74
Infective endocarditis 2 (4.0) 0 (0.0) 0.50
McCabe classiﬁcation
Rapidly fatal 19 (38.0) 15 (30.0) 0.40
Ultimately fatal 22 (44.0) 27 (54.0) 0.32
Non-fatal 9 (18.0) 8 (16.0) 0.79
Charlson weighted index
of co-morbidity (mean ± SD)
2.5 ± 1.4 2.2 ± 1.2 0.31
Underlying diseases
Liver cirrhosis 8 (16.0) 7 (14.0) 0.78
Cancer 13 (26.0) 8 (16.0) 0.22
Haematological malignancy 17 (34.0) 17 (34.0) > 0.99
End-stage renal disease 9 (18.0) 7 (14.0) 0.59
Infection acquired in ICU 7 (14.0) 10 (20.0) 0.42
Previous antibiotic use 37 (74.0) 41 (82.0) 0.33
Previous surgery 14 (28.0) 13 (26.0) 0.82
History of MRSA colonisation 15 (30.0) 15 (30.0) > 0.99
Neutropenia 14 (28.0) 13 (26.0) 0.82
Time to defervescence (days, mean) 6.7 ± 6.5 6.2 ± 5.8 0.76
Persistent bacteraemia at
72 h (days, mean ± SD)
18 (36.0) 16 (32.0) 0.67
Metastatic infection 12 (24.0) 7 (14.0) 0.20
Outcome
Cure 27 (54.0) 24 (48.0) 0.55
Recurrence 0 (0.0) 3 (6.0) 0.24
Deaths caused by factors
other than S. aureus
7 (14.0) 9 (18.0) 0.59
SAB-related deaths 16 (32.0) 14 (28.0) 0.85
Overall deaths 23 (46.0) 23 (46.0) > 0.99
SD, standard deviation; MRSA, methicillin-resistant Staphylococcus aureus; ICU,
intensive care unit.
aData are presented as the number (%) of patients unless indicated otherwise.
Table 5. Comparison of the outcome for patients in the
matched case-control studya with Staphylococcus aureus
bacteraemia who received appropriate and inappropriate
empirical therapy
Inappropriate empirical therapy (n = 50)
Diedb Survived
Appropriate empirical therapy (n = 50)
Diedb 1 13
Survived 15 21
aData are presented as the number of patients (p 0.85 in McNemar’s test).
bDenotes S. aureus-related deaths.
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glycopeptide use could be restricted if a patient
was stable (Fig. 2) and had an eradicable focus of
infection [17]. Alternatively, empirical use of
glycopeptides could be restricted to patients with
risk-factors for MRSA infection, such as a long
hospitalisation period [38]. Nevertheless, patients
with SAB who receive delayed appropriate anti-
staphylococcal treatment will require meticulous
observation for prolonged sepsis or complications
of infection.
Traditional multivariate adjustment methods
may not adjust adequately for bias related to the
choice of therapy. An adjustment using propen-
sity scores attempts to compensate for the prob-
lem created by the unequal chances of receiving
appropriate treatment [25]. Therefore, this analyt-
ical strategy has been used widely in clinical
settings where a randomised controlled trial is not
feasible [28], and yielded some constructive in-
sights in the present study. Nevertheless, the
study had important limitations. First, the study
may be underpowered to detect a statistical
difference in the cohort study and the matched-
cohort study. Two risk stratiﬁcation models were
used to adjust for potential differences between
the two groups, but these would not control for
any detection bias resulting from the limited
power of the study. Second, a limitation of
propensity score methods is that a covariable
related to treatment assignment, but not to out-
come, is handled in the same way as a covariable
with the same relationship to treatment assign-
ment and a strong relationship to outcome [25].
Thus, inclusion of irrelevant covariates reduces
the efﬁciency of the control on the relevant
covariates, although this limitation may not be
substantial in practice [25,40]. Third, inclusion of
methicillin resistance as a variable in the propen-
sity score can be criticised, since the clinician does
not know the methicillin resistance status when
choosing empirical therapy. However, previous
studies have shown that methicillin resistance is
associated with inappropriate empirical treatment
[5–7,17], and the local prevalence of methicillin
resistance may affect the choice of empirical
antibiotic regimen. In addition, it has been dem-
onstrated in univariate and multivariate analyses
that MRSA is an independent predictor for
inappropriate empirical treatment [41]. Fourth,
propensity scores are most useful when univari-
ate analysis indicates an association between a
certain therapy and an outcome, in which case the
propensity score controls for confounding factors
that affect this association. So, the ability of the
propensity score to provide a more accurate
estimate of the lack of an association, as in the
present study, is not entirely clear. Fifth, 44 (18%)
of the 238 patients had liver cirrhosis, reﬂecting
the high prevalence (8%) of chronic hepatitis B
virus infection among the general population in
Korea [17]. This may limit the general applicabil-
ity of the ﬁndings. Sixth, a simple measurement of
mortality might be considered to be a crude
measurement of the differences between two
groups. However, inappropriate empirical treat-
ment was associated with more persistent SAB
(Fig. 1) and longer time to defervescence. Finally, a
simple dichotamous classiﬁcation of empirical
antibiotic treatment (i.e., appropriate vs. inappro-
priate) could bias the results. Thus, if MRSA
isolates were particularly heterogeneous in their
expression of penicillin-binding protein 2a, it is
conceivable that some b-lactams that were classed
as inappropriate empirical treatment could have
had a suppressive effect against particular MRSA
isolates. However, almost all MRSA isolates in this
hospital have a high level of oxacillin resistance.
Overall, this observational study indicated that
an initial delay (< 48 h) in the prescription of
appropriate antibiotics resulted in an increased
risk of mortality in patients with SAB, but this
difference was not signiﬁcant. A larger prospec-
tive study will be required to conﬁrm these
ﬁndings.
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